Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MUSE: Anifrolumab in Systemic Lupus Erythematosus
NCT01438489Phase 2Completed
- Sponsor
- MedImmune
- Start
- Jan 2012
- Primary completion
- Apr 2015
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of anifrolumab in systemic lupus erythematosus (SLE) (3 arms), sponsored by MedImmune. Primary endpoints: Percentage of Participants Achieving an SLE Responder Index (SRI-4) Response With Oral Corticosteroids Tapering at Day 169 and Percentage of Type I Interferon (IFN) Test High Participants Achieving an SRI-4 Response With Oral Corticosteroids Tapering at Day 169. Started Jan 2012; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT01438489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01438489.